Organon & Co. - OGN STOCK NEWS

Organon (NYSE: OGN) will participate in a fireside chat at Citi’s 16th Annual BioPharma Virtual Conference on September 10, 2021, at 9:45 a.m. EDT. The session will feature CEO Kevin Ali and CFO Matthew Walsh. Investors, analysts, and the public are encouraged to view the live webcast here.

Organon focuses on women's health, offering over 60 products across various therapeutic areas, and recently acquired Alydia Health, specializing in postpartum hemorrhage. The company is headquartered in Jersey City, New Jersey.

Avestria Ventures, a venture capital firm based in the San Francisco-Bay Area, has successfully closed its Fund I aimed at investing in early-stage women’s health and female-led life sciences companies.

Founded by Linda Greub and Corinne Nevinny, Avestria targets sectors traditionally underserved by venture capital, with less than 1% of the $4T US healthcare market focused on women’s health as of 2020. Notable achievements include the June acquisition of portfolio company Alydia Health by Organon (NYSE: OGN) for up to $240M, indicating strong investor interest in these areas.

Organon (NYSE: OGN) reported a 5% increase in Q2 2021 revenue to $1,595 million, affirming its full-year guidance. The Board declared a quarterly dividend of $0.28 per share, payable on September 13, 2021. The Women's Health division grew by 19%, driven by NEXPLANON's 39% increase, while Biosimilars saw a 43% growth. However, Established Brands faced a 4% decline due to generic competition. Adjusted EBITDA dropped 19%, indicating challenges in cost management. Net income fell by 26% year-over-year.

Organon (NYSE: OGN) and ObsEva (NASDAQ: OBSV) have announced a licensing agreement for ebopiprant (OBE022), an investigational drug aimed at treating preterm labor. This agreement allows Organon exclusive global development and commercialization rights for ebopiprant, which could fill a critical gap in acute preterm labor treatment in the U.S. ObsEva will receive up to $500 million, including $25 million at signing, and tiered royalties on sales. The drug shows promise based on Phase 2a trial results, which indicated a significant reduction in preterm deliveries.

Organon (NYSE: OGN) is set to release its Q2 2021 financial results on August 12, 2021, prior to a conference call at 8:30 a.m. ET. Interested parties can access the live call via webcast. Following the call, a replay will be available on the company’s website. Organon focuses on women's health with over 60 products, including a strong reproductive health portfolio and expanding biosimilars business, supported by strong cash flows. The company aims for growth through acquisitions and collaborations in international markets.

Organon (NYSE: OGN) has received an unsolicited mini-tender offer from TRC Capital Investment Corporation, seeking to buy up to 3 million shares (1.18% of outstanding shares) at $28.63 each. This price is approximately 4.5% lower than Organon's last closing price of $29.98 on June 18, 2021. Organon recommends that stockholders reject the offer as it is below market value and subject to conditions. TRC's offer does not provide the same protections as larger tender offers, and investors are urged to consult market quotes and their advisors.

Organon (NYSE: OGN) has filed its Form 10-Q for Q1 2021, detailing financial results as a Merck spinoff. The financial statements abide by GAAP but do not represent the company's standalone financial condition. The company reaffirms its 2021 guidance, expecting revenue between $6.1 billion and $6.4 billion and an Adjusted EBITDA margin of 36.0% to 38.0%. Organon will report Q2 results on August 12, 2021, alongside its first standalone earnings call. The company focuses on women's health with a robust portfolio and aims to leverage growth opportunities globally.

Organon (NYSE: OGN) has successfully completed its acquisition of Alydia Health, a medical device company dedicated to preventing maternal morbidity and mortality due to postpartum hemorrhage (PPH). The acquisition, valued at $240 million, strengthens Organon's commitment to addressing women's healthcare needs. Alydia's Jada® System, which promotes uterine contraction to reduce excessive bleeding post-childbirth, received FDA marketing authorization in 2020. This strategic move expands Organon's portfolio into the medical device sector, enhancing its presence in reproductive health.

Organon (NYSE: OGN) celebrates its launch as a global women's health company with an opening bell ceremony at the NYSE. The company focuses on addressing women's health needs, emphasizing reproductive health and unique health issues. Organon's portfolio includes over 60 products across 140 markets, generating approximately $6.5 billion annually, with 80% from outside the U.S. Key growth areas include Women’s Health, Biosimilars, and Established Brands. The firm aims to enhance women's health through innovation and has a majority female board to guide its mission.